endpoint Introduces First Fully Configurable IRT System

SAN FRANCISCO, Jan. 13 /PRNewswire/ -- Today, endpoint (www.endpointclinical.com) launched PULSE, a fully configurable system that allows users to design and deploy clinical trial IRT systems in a fraction of the time and cost of other providers. Leveraging a background of more than 12 years designing Integrated Voice Response (IVR/IWR) technology for the Clinical Trial industry, endpoint designed PULSE to balance speed of deployment with flawless quality. PULSE simultaneously designs systems that can be accessed via the phone, web or mobile device.

"With PULSE we have dramatically changed how Integrated Voice Response (IVR/IWR) IRT systems are configured. Finally, there is a real solution that is delivered in half the time and with unprecedented cost savings," said Jonathan Dole, co-Founder and CEO of endpoint.

As the clinical trial industry evolves, sponsors are demanding Integrated Voice Response (IVRS) solutions that can be designed and deployed as rapidly as possible. PULSE, based on a data-driven platform, is a rules-based engine that can quickly and accurately deploy IRT systems with the highest degree of quality and a vast featureset. By utilizing the pre-validated functions in the PULSE engine, studies are deployed 40% more quickly and at much less cost. The cost savings is then passed on to the sponsor through a simplified pricing structure.

endpoint's IRT system takes advantage of the latest technology available today by:

• Allowing stakeholders 24/7 access to dynamic user reports that allow continual monitoring of study events.
• Offering reports that are completely configurable and editable by each user to meet their specifications.
• Allowing stakeholders to be continually updated with study events via email, fax or text messaging.

About endpoint

endpoint is an innovative company dedicated to the development of the leading Integrated Voice Response (IVR/IWR) technology platforms for the life sciences industry. endpoint's founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations.

SOURCE endpoint